Company
Sanegene Bio
Innovative genetic medicines for metabolic and autoimmune diseases. Powered by RNAi.
Also known as SanegeneBio
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Founded
- 2021
Claim, correct or request removal
Record updated 28 September 2026
About
SanegeneBio is a global biotech with a singular vision: Best-in-class RNAi medicines. We are focused on discovering and developing best-in-class genetic medicines for obesity, cardiometabolic, and autoimmune diseases using RNA interference (RNAi) technology.
Funding snapshot
- Total raised
- $110MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Series B, $110M2025-12-08
Funding rounds
- Series B
- $110M2025-12-08, Company stated
Loading relationship preview